{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:39:02Z","timestamp":1791491942752,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI120749"],"award-info":[{"award-number":["R01AI120749"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM127558"],"award-info":[{"award-number":["R01GM127558"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015581","name":"Houston Methodist Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jconrel.2025.114559","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:11:32Z","timestamp":1766247092000},"page":"114559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV"],"prefix":"10.1016","volume":"390","author":[{"given":"Ilaria","family":"Facchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camden","family":"Caffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thao Linh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda P.","family":"Pons-Faudoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hsia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Kimata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan E.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine Ying Xuan","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Grattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114559_bb0005","series-title":"Fact sheet 2024 - Latest global and regional HIV statistics on the status of the AIDS epidemic","author":"Unaids","year":"2024"},{"key":"10.1016\/j.jconrel.2025.114559_bb0010","author":"WHO"},{"key":"10.1016\/j.jconrel.2025.114559_bb0015","author":"HIV.gov"},{"key":"10.1016\/j.jconrel.2025.114559_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115009","article-title":"Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection","volume":"200","author":"Ullah Nayan","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114559_bb0025","author":"ClinicalTrials.gov"},{"issue":"13","key":"10.1016\/j.jconrel.2025.114559_bb0030","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly Lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Linda-Gail","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114559_bb0035","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/cid\/ciae472","article-title":"Comparison of at-home versus in-clinic receipt of long-acting injectable Cabotegravir\/Rilpivirine","volume":"80","author":"Kirk","year":"2025","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114559_bb0040","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2352-3018(24)00306-0","article-title":"Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother\u2013infant pairs (MTN-043): a phase 3B, open-label, randomised trial","volume":"12","author":"Noguchi","year":"2025","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114559_bb0045","article-title":"Preventive efficacy of a Tenofovir Alafenamide fumarate Nanofluidic implant in SHIV-challenged nonhuman Primates","volume":"4","author":"Pons-Faudoa","year":"2021","journal-title":"Adv Ther (Weinh)"},{"key":"10.1016\/j.jconrel.2025.114559_bb0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2018.08.010","article-title":"Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis","volume":"286","author":"Chua","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114559_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2019.05.037","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis","volume":"306","author":"Pons-Faudoa","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114559_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2023.12.031","article-title":"Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques","volume":"366","author":"Pons-Faudoa","year":"2024","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2025.114559_bb0065","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41591-021-01479-3","article-title":"Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial","volume":"27","author":"Matthews","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114559_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114166","article-title":"Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention","volume":"386","author":"Le","year":"2025","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2025.114559_bb0075","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.1016\/S2352-3018(25)00079-7","article-title":"Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in south African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trial","volume":"12","author":"Gengiah","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jconrel.2025.114559_bb0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jconrel.2021.10.021","article-title":"Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones","volume":"340","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114559_bb0085","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.1038\/s41598-022-11020-2","article-title":"Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis","volume":"12","author":"Gunawardana","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114559_bb0090","article-title":"A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques","volume":"64","author":"T","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2025.114559_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123110","article-title":"The effect of the foreign body response on drug elution from subdermal delivery systems","volume":"317","author":"Capuani","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114559_bb0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2023.04.037","article-title":"Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates","volume":"358","author":"Pons-Faudoa","year":"2023","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114559_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052880","article-title":"CAPRISA 018: a phase I\/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women","volume":"12","author":"Gengiah","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114559_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26426","article-title":"Acceptability of an annual tenofovir alafenamide implant for HIV prevention in south African women: findings from the CAPRISA 018 phase I clinical trial","volume":"28","author":"Gengiah","year":"2025","journal-title":"J. Int. AIDS Soc."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114559_bb0115","article-title":"A randomized, double-blind, placebo-controlled, phase 1 trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection","volume":"92","author":"Matthews","year":"2023","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2025.114559_bb0120","series-title":"Conference on Retroviruses and Opportunistic Infections; March 3\u20136, 2024; Denver, CO","article-title":"Phase 1 study of cabotegravir long-acting injectable formulations supports \u22654-monthly dose interval","author":"Han","year":"2024"},{"issue":"8016","key":"10.1016\/j.jconrel.2025.114559_bb0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-024-07426-9","article-title":"Adhesive anti-fibrotic interfaces on diverse organs","volume":"630","author":"Wu","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114559_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10300","article-title":"Advanced strategies to thwart foreign body response to implantable devices","volume":"7","author":"Capuani","year":"2022","journal-title":"Bioeng. Transl. Med."},{"issue":"702","key":"10.1016\/j.jconrel.2025.114559_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg2887","article-title":"Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates","volume":"15","author":"Pons-Faudoa","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2025.114559_bb0140","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114559_bb0145","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10875-010-9440-3","article-title":"Molecular mechanism of NLRP3 Inflammasome activation","volume":"30","author":"Jin","year":"2010","journal-title":"J. Clin. Immunol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114559_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000354","article-title":"MCC950\/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition","volume":"17","author":"Vande Walle","year":"2019","journal-title":"PLoS Biol."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114559_bb0155","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20242403","article-title":"Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action","volume":"222","author":"Wilhelmsen","year":"2025","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114559_bb0160","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114559_bb0165","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem. Sci."},{"issue":"32","key":"10.1016\/j.jconrel.2025.114559_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301571","article-title":"Selective immunosuppression targeting the NLRP3 inflammasome mitigates the foreign body response to implanted biomaterials while preserving angiogenesis","volume":"12","author":"Chan","year":"2023","journal-title":"Adv. Healthc. Mater."},{"issue":"12","key":"10.1016\/j.jconrel.2025.114559_bb0175","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2115857119","article-title":"Prevention of the foreign body response to implantable medical devices by inflammasome inhibition","volume":"119","author":"Barone","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.114559_bb0180","article-title":"Selective NLRP3 inflammasome inhibitor MCC950 suppresses inflammation and facilitates healing in vascular materials","volume":"10","author":"Grant","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jconrel.2025.114559_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114559_bb0190","article-title":"Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1\u2013infected adults","volume":"75","author":"Gallant","year":"2017","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2025.114559_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115862","article-title":"Biktarvy for the treatment of HIV infection: Progress and prospects","volume":"217","author":"De Clercq","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114559_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119623","article-title":"Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications","volume":"587","author":"Sizovs","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114559_bb0205","article-title":"Extending drug release from implants via transcutaneous refilling with solid therapeutics","volume":"5","author":"Di Trani","year":"2022","journal-title":"Adv Ther (Weinh)"},{"key":"10.1016\/j.jconrel.2025.114559_bb0210","series-title":"bioRxiv, p. 2022.12.15.520646","article-title":"Ultra-long-acting refillable nanofluidic implant confers full protection against SHIV infection in non-human primates","author":"Pons-Faudoa","year":"2022"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114559_bb0215","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1038\/s41596-023-00881-0","article-title":"An end-to-end workflow for multiplexed image processing and analysis","volume":"18","author":"Windhager","year":"2023","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114559_bb0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10544-024-00713-2","article-title":"3D bioprinted mesenchymal stem cell laden scaffold enhances subcutaneous vascularization for delivery of cell therapy","volume":"26","author":"Bo","year":"2024","journal-title":"Biomed. Microdevices"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114559_bb0225","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/s41467-018-04133-8","article-title":"Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale","volume":"9","author":"Bruno","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114559_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102258","article-title":"Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy","volume":"56","author":"Liu","year":"2024","journal-title":"Nano Today"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114559_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10594","article-title":"Intratumoral nanofluidic system enhanced tumor biodistribution of PD-L1 antibody in triple-negative breast cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114559_bb0240","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J. Immunol. Methods"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114559_bb0245","article-title":"Pharmacokinetics of bictegravir in older Japanese people living with HIV-1","volume":"11","author":"Akira","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114559_bb0250","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s10020-022-00594-2","article-title":"The emerging role of pyroptosis-related inflammasome pathway in atherosclerosis","volume":"28","author":"Xu","year":"2022","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114559_bb0255","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1038\/s41467-020-19906-3","article-title":"Foreign body responses in mouse central nervous system mimic natural wound responses and alter biomaterial functions","volume":"11","author":"O\u02bcShea","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114559_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.609297","article-title":"Biomaterials-mediated regulation of macrophage cell fate","volume":"8","author":"Liu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.114559_bb0265","article-title":"T cells in fibrosis and fibrotic diseases","volume":"11","author":"Mengjuan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114559_bb0270","author":"Chung"},{"issue":"12","key":"10.1016\/j.jconrel.2025.114559_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/bioengineering8120205","article-title":"Implantable drug delivery systems and foreign body reaction: traversing the current clinical landscape","volume":"8","author":"Fayzullin","year":"2021","journal-title":"Bioengineering"},{"key":"10.1016\/j.jconrel.2025.114559_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114559_bb0285","article-title":"Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases","volume":"185","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:28:32Z","timestamp":1781702912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925011733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"alternative-id":["S0168365925011733"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114559","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114559"}}